164 related articles for article (PubMed ID: 37548746)
21. High Real-World Medication Adherence and Durable Clinical Benefit in Medicare Patients Treated with 5-Alpha Reductase Inhibitors for Benign Prostatic Hyperplasia.
Zhang H; Frendl DM; Wang Z; Olumi AF
J Urol; 2020 Aug; 204(2):325-331. PubMed ID: 32167867
[TBL] [Abstract][Full Text] [Related]
22. Comparing Clinical and Economic Outcomes Associated with Early Initiation of Combination Therapy of an Alpha Blocker and Dutasteride or Finasteride in Men with Benign Prostatic Hyperplasia in the United States.
DerSarkissian M; Xiao Y; Duh MS; Lefebvre P; Swensen AR; Bell CF
J Manag Care Spec Pharm; 2016 Oct; 22(10):1204-14. PubMed ID: 27668569
[TBL] [Abstract][Full Text] [Related]
23. Association of physician specialty and medical therapy for benign prostatic hyperplasia.
Han LC; Kim SP; Gross CP; Ross JS; Van Houten HK; Smaldone MC; Krambeck AE; Shah ND
Med Care; 2014 Feb; 52(2):128-36. PubMed ID: 24423810
[TBL] [Abstract][Full Text] [Related]
24. Drug treatment of benign prostatic hyperplasia and hospital admission for BPH-related surgery.
Souverein PC; Erkens JA; de la Rosette JJ; Leufkens HG; Herings RM
Eur Urol; 2003 May; 43(5):528-34. PubMed ID: 12705998
[TBL] [Abstract][Full Text] [Related]
25. Monotherapy versus combination drug therapy for the treatment of benign prostatic hyperplasia.
Logan YT; Belgeri MT
Am J Geriatr Pharmacother; 2005 Jun; 3(2):103-14. PubMed ID: 16129387
[TBL] [Abstract][Full Text] [Related]
26. Patient characteristics and treatment patterns for patients with benign prostatic hyperplasia, erectile dysfunction or co-occurring benign prostatic hyperplasia and erectile dysfunction in general practices in the UK: a retrospective observational study.
Ilo D; Raluy-Callado M; Graham-Clarke P; Sadasivan R; Birt J; Donaldson R; Zhu E; Kirby MG; Neasham D
Int J Clin Pract; 2015 Aug; 69(8):853-62. PubMed ID: 26011100
[TBL] [Abstract][Full Text] [Related]
27. 5-Alpha Reductase Inhibitors and the Risk of Prostate Cancer Mortality in Men Treated for Benign Prostatic Hyperplasia.
Wallner LP; DiBello JR; Li BH; Van Den Eeden SK; Weinmann S; Ritzwoller DP; Abell JE; D'Agostino R; Loo RK; Aaronson DS; Richert-Boe K; Horwitz RI; Jacobsen SJ
Mayo Clin Proc; 2016 Dec; 91(12):1717-1726. PubMed ID: 28126151
[TBL] [Abstract][Full Text] [Related]
28. Benign prostatic hyperplasia is a significant risk factor for bladder cancer in diabetic patients: a population-based cohort study using the National Health Insurance in Taiwan.
Tseng CH
BMC Cancer; 2013 Jan; 13():7. PubMed ID: 23286275
[TBL] [Abstract][Full Text] [Related]
29. Does Prostate Size Predict the Development of Incident Lower Urinary Tract Symptoms in Men with Mild to No Current Symptoms? Results from the REDUCE Trial.
Simon RM; Howard LE; Moreira DM; Roehrborn C; Vidal AC; Castro-Santamaria R; Freedland SJ
Eur Urol; 2016 May; 69(5):885-91. PubMed ID: 26724841
[TBL] [Abstract][Full Text] [Related]
30. Clinical and economic impact of early versus delayed 5-alpha reductase inhibitor therapy in men taking alpha blockers for symptomatic benign prostatic hyperplasia.
Kruep EJ; Hogue SL; Eaddy MT; Chandra MD
P T; 2011 Aug; 36(8):493-507. PubMed ID: 21935297
[TBL] [Abstract][Full Text] [Related]
31. Poor clinical guideline adherence and inappropriate testing for incident lower urinary tract symptoms associated with benign prostatic hyperplasia.
Welliver C; Feinstein L; Ward JB; Kirkali Z; Martinez-Miller EE; Matlaga BR; McVary K
Prostate Cancer Prostatic Dis; 2022 Feb; 25(2):269-273. PubMed ID: 34545201
[TBL] [Abstract][Full Text] [Related]
32. Use of 5-alpha-reductase inhibitors did not increase the risk of cardiovascular diseases in patients with benign prostate hyperplasia: a five-year follow-up study.
Hsieh TF; Yang YW; Lee SS; Lin TH; Liu HH; Tsai TH; Chen CC; Huang YS; Lee CC
PLoS One; 2015; 10(3):e0119694. PubMed ID: 25803433
[TBL] [Abstract][Full Text] [Related]
33. The Cardiovascular Safety of Five-Alpha-Reductase Inhibitors Among Men with Benign Prostatic Hyperplasia: A Population-Based Cohort Study.
Ayele HT; Reynier P; Azoulay L; Platt RW; Benayoun S; Filion KB
Am J Med; 2023 Oct; 136(10):1000-1010.e7. PubMed ID: 37481022
[TBL] [Abstract][Full Text] [Related]
34. Association of clinical benign prostate hyperplasia with prostate cancer incidence and mortality revisited: a nationwide cohort study of 3,009,258 men.
Ørsted DD; Bojesen SE; Nielsen SF; Nordestgaard BG
Eur Urol; 2011 Oct; 60(4):691-8. PubMed ID: 21705134
[TBL] [Abstract][Full Text] [Related]
35. Efficacy and safety of Finasteride (5 alpha-reductase inhibitor) monotherapy in patients with benign prostatic hyperplasia: A critical review of the literature.
Busetto GM; Del Giudice F; D'Agostino D; Romagnoli D; Minervini A; Rocco B; Antonelli A; Celia A; Schiavina R; Cindolo L; Chung BI; Kim JH; Maggi M; Sciarra A; De Berardinis E; Porreca A
Arch Ital Urol Androl; 2020 Jan; 91(4):205-210. PubMed ID: 31937082
[TBL] [Abstract][Full Text] [Related]
36. Tamsulosin and the risk of dementia in older men with benign prostatic hyperplasia.
Duan Y; Grady JJ; Albertsen PC; Helen Wu Z
Pharmacoepidemiol Drug Saf; 2018 Mar; 27(3):340-348. PubMed ID: 29316005
[TBL] [Abstract][Full Text] [Related]
37. The association of α-blockers and 5-α reductase inhibitors in benign prostatic hyperplasia with fractures.
Lim SY; Laengvejkal P; Panikkath R; Nugent K
Am J Med Sci; 2014 Jun; 347(6):463-71. PubMed ID: 24270079
[TBL] [Abstract][Full Text] [Related]
38. The Use of 5-Alpha Reductase Inhibitors to Manage Benign Prostatic Hyperplasia and the Risk of All-cause Mortality.
Wallner LP; DiBello JR; Li BH; Van Den Eeden SK; Weinmann S; Ritzwoller DP; Abell JE; D'Agostino R; Loo RK; Aaronson DS; Horwitz RI; Jacobsen SJ
Urology; 2018 Sep; 119():70-78. PubMed ID: 29906480
[TBL] [Abstract][Full Text] [Related]
39. Combination of α-blocker and 5α-reductase inhibitor for treatment of benign prostatic hyperplasia.
Kang D; Hu C; Fu Y; Wang D
Clin Invest Med; 2017 Oct; 40(5):E200-E210. PubMed ID: 29061225
[TBL] [Abstract][Full Text] [Related]
40. Association of Treatment With 5α-Reductase Inhibitors With Time to Diagnosis and Mortality in Prostate Cancer.
Sarkar RR; Parsons JK; Bryant AK; Ryan ST; Kader AK; McKay RR; D'Amico AV; Nguyen PL; Hulley BJ; Einck JP; Mundt AJ; Kane CJ; Murphy JD; Rose BS
JAMA Intern Med; 2019 Jun; 179(6):812-819. PubMed ID: 31058923
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
